

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

Tirzepatide - 10mg

Tested for: Latitude 40 Aminos

www.lat40aminos.com

COA #: COA-2026-BBCEKH

Lot Number: Lot: TR10-1

Labeled Content: 10mg

Volume: 3mL

Analysis Date: 07/28/2026

Appearance: Good

Volume: 3mL

Date Received: 07/13/2026

PASS



Scan to verify
authenticity at ils-lab.com
Access Code: DPR9DGB6

Method: Purity, Identity & Quantitation (HPLC)

Identity

Tirzepatide

Peptide Purity

99.35%



Fentanyl Free


Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.35%	%	PASS
Net Peptide Content	Report Only	10.26	mg	N/A
Identity (HPLC-RTM)	Tirzepatide	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS



Tirzepatide 10mg - Lot: TR10-1

HPLC Chromatogram



Tirzepatide 10mg - Lot: TR10-1: UV Chromatogram

Notes & Methodology

- Date Tested: 07/28/2026. Methods: Purity, Identity & Quantitation (HPLC).
- The sample was confirmed to be Tirzepatide by HPLC. Identification by chromatographic retention time comparison with a reference standard.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.



Handwritten signature

Dr. Greg Kalyuzhny

Lab Director

7/28/2026

COA #: COA-2026-BBCEKH

Access Code: DPR9DGB6

Verify: portal.ils-lab.com

Issued: 7/28/2026



Client Latitude 40 Aminos

Analyzed 08/10/2026

This Certificate of Analysis certifies that the sample listed herein was tested by SteriGenix using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	Tirzepatide	Form	Lyophilized
Batch	SGX-L4A-2026-0727-X45	Labeled Qty	20MG
Mol. Formula	C225H348N48O68	CAS Number	2023788-19-2
Cap Color	Blue	Crimp Color	Silver
Appearance	White Powder		

TEST RESULTS

	REFERENCE STANDARD	RESULT	
Identity Confirmation (LC-MS)	Tirzepatide	Tirzepatide	✓
Batch Avg Purity (HPLC)	(>98%)	99.76	✓
Net Peptide Content	20MG ± 10%	20.89	✓

HEAVY METAL SCREENING


No data.

BATCH CONFORMITY RESULTS

No data.

HPLC CHROMATOGRAM

HPLC CHROMATOGRAM · TIRZEPATIDE 20MG	DETECTOR: UV 214 NM · 08/10/2026
--------------------------------------	----------------------------------



SAMPLE PHOTOS



Dr. R. Caldwell

ANALYST
ID: AN-3271

Dr. P. Andersen

QC REVIEWER
ID: QR-5418

Dr. H. Whitman

QA DIRECTOR
ID: QA-1090



sterigenixanalytical.com/verify

Report#: RPT-2026-648734
Access Code: SGX-L4A-2026-0727-X45



SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	Tirzepatide
Lot / Batch	RVA-TR-318A09	Label Claim	20 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Blue
Crimp Color	Silver / Aluminum	Contents Color	White
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4813.527 Da	4813.263 Da	PASS
Purity research screen	≥ 99.25 area %	99.38%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 20 mg	Vial A: 20.95 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity

LC-MS (ESI+)

4813.263 Da

every vial within ± 1 Da of 4813.527 Da

PASS

Theoretical mass

4813.527 Da

Acceptance

within ± 1 Da

Vial A

4813.263 Da · PASS

4813.263 Da PASS

2 Purity

RP-HPLC 214nm (USP <621>)

99.38%

≥ 99.25 area %

PASS

Acceptance

$\geq 99.25\%$

Vial A

99.38% · PASS

Criterion
source

**Axiom Analytics SPEC-PURITY-001, Revision 1, effective
2026-08-31**

99.38% PASS

limit 99.25%

3 Net Peptide Content

Quantitative HPLC vs reference std

Vial A: 20.95 mg

every vial within $\pm 10\%$ of 20 mg

PASS

Target

20 mg ($\pm 10\%$)

Vial A

20.95 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

20.95 mg PASS

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen

Target
panel

**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA
gene (FAM)**

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen


none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

LC-MS Mass Spectrum · Vial A · LC-MS (ESI+)



Recorded deconvoluted average mass: 4813.263 Da


Charge	Observed m/z	Deconvoluted mass (Da)	Relative intensity (%)
--------	--------------	------------------------	------------------------

4+	1204.324	4813.266	50.4
5+	963.662	4813.272	100.0
6+	803.216	4813.252	50.4
7+	688.616	4813.262	6.5
8+	602.665	4813.263	0.2



SCAN TO VERIFY

HPLC Chromatogram · Vial A · RP-HPLC 214 nm



Peak	Retention time (min)	Area %
1	6.680	0.108
2	7.360	0.335
3	7.580	99.380
4	8.332	0.098
5	8.642	0.030
6	8.962	0.049



Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.



CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)



Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US
AX-2026-4556-XADR
Tirzepatide · Lot RVA-TR-318A09
Issued Oct 20, 2026 PT · v1
Verify: 8819-1FEF-3EDC



Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:1beff2e80db44920dde5db5c...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:40dbbc00d08dde9fe816dfa2...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:9d2bfed3a10ed64675978201...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-4556-XADR>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: c3b32b0b5c41943893736ee6a7fe4c8c23243e25c5b09146ea717a34e43030ec...
Seal: ed25519:d19172f93ab04f89b491c34a58ac31d9f162c8d4...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.



Client Latitude 40 Aminos

Analyzed 08/10/2026

This Certificate of Analysis certifies that the sample listed herein was tested by SteriGenix using validated analytical methods and was found to meet the stated specifications at the time of analysis.

SAMPLE INFORMATION

Product	Tirzepatide	Form	Lyophilized
Batch	SGX-L4A-2026-0727-S63	Labeled Qty	30MG
Mol. Formula	C225H348N48O68	CAS Number	2023788-19-2
Cap Color	Pink	Crimp Color	Silver
Appearance	White Powder		

TEST RESULTS

	REFERENCE STANDARD	RESULT	
Identity Confirmation (LC-MS)	Tirzepatide	Tirzepatide	✓
Batch Avg Purity (HPLC)	(>98%)	99.51	✓
Net Peptide Content	30MG ± 10%	30.44	✓

HEAVY METAL SCREENING


No data.

BATCH CONFORMITY RESULTS

No data.

HPLC CHROMATOGRAM

HPLC CHROMATOGRAM · TIRZEPATIDE 30MG	DETECTOR: UV 214 NM · 08/10/2026
--------------------------------------	----------------------------------



SAMPLE PHOTOS



AS RECEIVED

RECONSTITUTED (BACT. WATER) — CLARITY
CHECK

Dr. R. Caldwell

ANALYST
ID: AN-3271

Dr. P. Andersen

QC REVIEWER
ID: QR-5418

Dr. H. Whitman

QA DIRECTOR
ID: QA-1090



sterigenixanalytical.com/verify

Report#: RPT-2026-749961

Access Code: SGX-L4A-2026-0727-S63



Latitude 40 Aminos
Latitude40labs@gmail.com

SAMPLE NAME:
SAMPLE CODE:
RECEIVED DATE:
PUBLISHED DATE:

Tirzepatide
98ZF-KDQQ
08/26/2026
08/29/2026



DECLARED IDENTITY: Tirzepatide
MATRIX TYPE: PEPTIDE
SAMPLE NAME: Tirzepatide
SAMPLE SIZE: 40.0 mg
LOT CODE: RRLC260627140X




45.124 mg
Total Quantity



99.928%
Total Blend Purity

Sample	Test	Specification	Result	Status
Tirzepatide	IDENTITY	Tirzepatide	Tirzepatide	CONFORMS
Tirzepatide	QUANTITY	MEASURE	45.124 mg	MEASURED
Tirzepatide	PURITY	> 98.0%	99.928%	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:

Anthony Burke PhD
Lab Manager
08/29/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
08/29/2026

ACCUMARKLABS.COM
98ZF-KDQQ
08/29/2026





SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

■ L1
Identity

■ L2
Purity

■ L3
Net Peptide Content

■ L4
Sterility

■ L8
Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A - right

Brand	Latitude 40 Aminos	Product	Tirzepatide
Lot / Batch	RVA-TR-318A39	Label Claim	60 mg
Matrix	Lyophilized powder	Sample Count	1
Vial Size	3mL	Cap Color	Yellow
Crimp Color	Silver / Aluminum	Contents Color	White
Seal Intact	Yes	Condition	sealed, intact
Received	Oct 1, 2026 PT	Sampling	client submitted



Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 4813.527 Da	4813.744 Da	PASS
Purity research screen	≥ 99.25 area %	99.88%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 60 mg	Vial A: 61.81 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS



Layer Results

1 Identity

LC-MS (ESI+)

4813.744 Da

every vial within ± 1 Da of 4813.527 Da

PASS

Theoretical mass

4813.527 Da

Acceptance

within ± 1 Da

Vial A

4813.744 Da · PASS

4813.744 Da PASS

2 Purity

RP-HPLC 214nm (USP <621>)

99.88%

≥ 99.25 area %

PASS

Acceptance

$\geq 99.25\%$

Vial A

99.88% · PASS

Criterion
source

**Axiom Analytics SPEC-PURITY-001, Revision 1, effective
2026-08-31**

99.88% PASS

limit 99.25%

3 Net Peptide Content

Quantitative HPLC vs reference std

Vial A: 61.81 mg

every vial within $\pm 10\%$ of 60 mg

PASS

Target

60 mg ($\pm 10\%$)

Vial A

61.81 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

61.81 mg PASS

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen

Target
panel

**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA
gene (FAM)**

Run controls valid.



8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:e6403d327a9827241ac6fec2...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:85f66faaa74506a866674f98...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:11c818872c90d26babe572a7...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-3542-T72Y>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 3feb22c53e42aeeebfb4842945fb7933a7de07fd714b27985fd1b96d1cfb0d66...

Seal: ed25519:c5ea66800ac0a90d5bac5456facc9d1311efd9d8...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.